Premium
The pharmacology of the internal anal sphincter and new treatments of ano‐rectal disorders
Author(s) -
Cook T. A.,
Brading A. F.,
Mortensen N. J. McC.
Publication year - 2001
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2001.00995.x
Subject(s) - internal anal sphincter , medicine , urethral sphincter , botulinum toxin , sphincter , hypertonia , muscarinic acetylcholine receptor , cholinergic , pharmacology , receptor , urology , anesthesia , surgery , urinary incontinence , anal canal , rectum
Surgical options for faecal incontinence in the presence of intact sphincters are limited. Furthermore, in patients with fissures, lateral sphincterotomy reduces anal sphincter hypertonia but there has been concern about complications. A greater understanding of the basic pharmacology of the internal anal sphincter has led to the development of novel treatments for both these disorders. A Medline review was undertaken for internal anal sphincter pharmacology, anal fissures and faecal incontinence. This review is based on these articles and those found by further cross‐referencing. Nitric oxide released from non‐adrenergic non‐cholinergic nerves is the main inhibitory agent in the internal anal sphincter. Relaxations are also mediated through β‐adrenoceptors and muscarinic receptors. Stimulation of α‐receptors results in contraction. Calcium and its entry through L ‐type calcium channels is important for the maintenance of tone. Nitric oxide donors produce reductions in resting anal tone and heal fissures but are associated with side‐effects. Muscarinic agents and calcium channel antagonists show promise as low side‐effect alternatives. Botulinum toxin appears more efficacious than other agents in healing fissures. To date, α‐receptor agonists have been disappointing at improving incontinence. Further understanding of the pharmacology of the internal anal sphincter may permit the development of new agents to selectively target the tissue with greater efficacy and fewer side‐effects.